PD55-05 METASTASIS-DIRECTED RADIATION THERAPY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive IV (PD55)1 Sep 2021PD55-05 METASTASIS-DIRECTED RADIATION THERAPY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER Andre Miranda, Jeffrey Howard, Mark McLaughlin, Xiaosong Meng, Aurelie Garant, Aditya Bagrodia, Vitaly Margulis, Yair Lotan, Raquibul Hannan, Neil Desai, and Solomon Woldu Andre MirandaAndre Miranda More articles by this author , Jeffrey HowardJeffrey Howard More articles by this author , Mark McLaughlinMark McLaughlin More articles by this author , Xiaosong MengXiaosong Meng More articles by this author , Aurelie GarantAurelie Garant More articles by this author , Aditya BagrodiaAditya Bagrodia More articles by this author , Vitaly MargulisVitaly Margulis More articles by this author , Yair LotanYair Lotan More articles by this author , Raquibul HannanRaquibul Hannan More articles by this author , Neil DesaiNeil Desai More articles by this author , and Solomon WolduSolomon Woldu More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002089.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Metastasis-directed radiation therapy (MDRT) may improve oncologic and quality of life outcomes in patients with metastatic cancer, but data on its use in metastatic bladder cancer is severely limited and is primarily from the pre-immunotherapy era. We sought to review our recent institutional experience with MDRT in patients with metastatic bladder cancer following radical cystectomy. METHODS: We reviewed records of patients who underwent radical cystectomy and subsequent MDRT at our institution between 2009 and 2020. Baseline demographic and clinical/pathologic factors were collected, as were details of treatment including systemic therapy and MDRT. Cases were categorized by treatment intent as consolidative (intended to prolong survival) and palliative (intended only to relieve symptoms). Response to treatment, survival, and toxicity outcomes were reviewed. RESULTS: A total of 52 patients underwent MDRT following radical cystectomy. MDRT was categorized as consolidative in 40% of cases and palliative in 60%. Toxicity (CTCAE Grade ≥2) was reported in 15% of patients, none of which exceeded Grade 3. Most patients undergoing consolidative MDRT were treated with SBRT techniques (76%) and a majority (67%) received concurrent treatment with an immuno-oncology agent. Among patients treated with consolidative intent, 2-year progression-free and overall survival were 19% and 60%, respectively. CONCLUSIONS: This represents one of the largest published series of metastasis-directed radiation therapy (MDRT) in metastatic bladder cancer. MDRT is safe and well-tolerated by a majority of patients. A majority of patients treated with consolidative intent survived ≥2 years from treatment, suggesting that some appropriately selected patients can achieve long-term survival. Further prospective research is required to define the role of MDRT in metastatic bladder cancer. Source of Funding: This study was funded internally by the UT Southwestern Department of Urology. © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e998-e999 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andre Miranda More articles by this author Jeffrey Howard More articles by this author Mark McLaughlin More articles by this author Xiaosong Meng More articles by this author Aurelie Garant More articles by this author Aditya Bagrodia More articles by this author Vitaly Margulis More articles by this author Yair Lotan More articles by this author Raquibul Hannan More articles by this author Neil Desai More articles by this author Solomon Woldu More articles by this author Expand All Advertisement Loading ...